<DOC>
	<DOCNO>NCT01823991</DOCNO>
	<brief_summary>The purpose study examine safety influence intervention ( COGNUTRIN ) use nutritional supplement ( n-3 fatty acid blueberry anthocyanins ) cognitive performance breast cancer survivor follow chemotherapy . The investigator ' goal treat lessen late effect cancer treatment . The supplement use combination follow : ( 1 ) VitaBlue ( 40 % polyphenolics , 12.5 % anthocyanins blueberry ( BB ) ( 2 ) n-3 fatty acid - Lovaza .</brief_summary>
	<brief_title>COGNUTRIN Breast Cancer Survivors</brief_title>
	<detailed_description>This pilot study evaluate feasibility administration nutritional supplement placebo patient population perform cognitive function test baseline post supplementation . This randomized , double-blind pilot study COGNUTRIN v . Placebo . Participants equal chance ( like flip coin ) either study group . Neither participant study doctor able choose study group participant . Participants know study doctor know study group participant .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Cases Stage IIIIIA Breast Cancer complete adjuvant treatment anthracyclines and/or taxanes + Radiation therapy within past 6 month ( +/ 7 day ) ( subject concurrent endocrine therapy ( TAM , Aromatase inhibitor also eligible participate standard care patient population ) Able understand sign inform consent Fluent reading , comprehension communication English language No evidence dementia Mini Mental State Examination ( MMSE ) &gt; =23 evidence cognitive impairment Must aware nature current medical condition must willing give consent inform experimental nature therapy , alternative , potential benefit , sideeffects , risk discomfort Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 ( Karnofsky score &gt; 60 % ) Acceptable hemoglobin hematocrit level base complete blood count ( CBC ) Must willing monitor adequacy nutritional intake intervention , current standard clinical practice Use estrogens ( oral , dermal vaginal ) , progesterone ( oral topical ) , androgens , Raloxifene Tamoxifen previous 3 month Use counter steroid hormonal supplement include dehydroepiandrosterone ( DHEA ) Patients advanced Stage IIIIB IV breast cancer cancer Use n3 fatty acid high dose antioxidant supplement provide trial History know allergy component study supplement Renal liver disease Concurrent participation another chemoprevention trial Evidence bleeding diathesis coagulopathy Metabolic abnormality ( e.g . thyroid disorder , insulin dependent diabetes , rheumatologic disease etc . ) Known claustrophobia , presence pacemaker and/or ferromagnetic material body would prohibit MRI image Medical history concussion Other acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make potential participant inappropriate entry study</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>polyphenolics</keyword>
	<keyword>anthocyanins</keyword>
	<keyword>n-3 fatty acid</keyword>
</DOC>